Antibiotic Resistance Therapeutics Market Research Report 2025-2029 - Search for Alternatives to Antibiotics Creates New Global Goldrush [Yahoo! Finance]
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Yahoo! Finance
Therapy Type, with Situation Analysis, Executive, and Investor Guides" report has been added to ResearchAndMarkets.com's offering. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report - and the study summarizes what technologies they are using. Antimicrobial Resistance is creating new kinds of infections and "superbugs" that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. This report identifies the 6 key large opportunities in this space and developed market forecasts. The research looks at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This research makes you the expert in your organization. Make investment decisions and valuations with confidence using the latest data. Key Topics Covered:
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $27.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement LawsuitBusiness Wire
- Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)Business Wire
- Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) [Yahoo! Finance]Yahoo! Finance
ENTA
Earnings
- 11/25/24 - Miss
ENTA
Sec Filings
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- 12/10/24 - Form 4
- ENTA's page on the SEC website